263764-92-7

Upstream product

• 93-40-3 (3,4-Dimethoxyphenyl)acetic acid 
• 105-36-2 ethyl bromoacetate 

Downstream Products

• 1320275-54-4 4-(2-(cyclohexylamino)ethoxy)-3-(3,4-dimethoxyphenyl)furan-2(5H)-one 
• 1320275-55-5 3-(3,4-dimethoxyphenyl)-4-(2-(piperidin-1-yl)ethoxy)furan-2(5H)-one 
• 1320275-56-6 3-(3,4-dimethoxyphenyl)-4-(2-(4-methylpiperazin-1-yl)ethoxy)furan-2(5H)-one 
• 1375540-58-1 4-(3-chlorophenylamino)-3-(3,4-dimethoxyphenyl)furan-2(5H)-one 
• 1346463-88-4 3-(3,4-dimethoxyphenyl)-4-(2-methoxyphenylamino)furan-2(5H)-one 
• 1375540-57-0 4-(2-chlorophenylamino)-3-(3,4-dimethoxyphenyl)furan-2(5H)-one 
• 263765-03-3 toluene-4-sulfonic acid 4-(3,4-dimethoxy-phenyl)-5-oxo-2,5-dihydro-furan-3-yl ester 
• 263764-95-0 3-(3,4-dimethoxyphenyl)-4-bromo-5H-furan-2-one 
• 263764-91-6 3-(3,4-dimethoxyphenyl)-4-hydroxyfuran-2(5H)-one 

Relevant academic research and scientific papers

4-azidotetronic acids: A new class of azido derivatives

4-Azidotetronic derivatives bearing different substituent groups on the carbon atom in position 3 were easily obtained by reaction of the corresponding 4-bromotetronic compounds with sodium azide in methanol at room temperature.

Synthesis, molecular docking and biological evaluation of 3-arylfuran-2(5H)-ones as anti-gastric ulcer agent

3-Arylfuran-2(5H)-one derivatives show good antibacterial activity and were determined as tyrosyl-tRNA synthetase (TyrRS) inhibitors. In a systematic medicinal chemistry exploration, we demonstrated chemical opportunities to treat infections caused by Hel

Structure and antibacterial activity of 3-(3,4-dimethoxyphenyl) furan-2(5H)-ones

Crystalline hydrate of the title compound (5), C19H 26N2O5·2(H2O), was structurally characterized by single crystal X-ray diffraction. It crystallizes in monoclinic system space group P 21/c with a =

Synthesis, structure, molecular docking, and structure-activity relationship analysis of enamines: 3-Aryl-4-alkylaminofuran-2(5H)-ones as potential antibacterials

Thirty-one 3-aryl-4-alkylaminofuran-2(5H)-ones were designed, prepared and tested for their antibacterial activity. Some of them showed significant antibacterial activity against Gram-positive organisms, especially against Staphylococcus aureus ATCC 25923, but all were inactive against Gram-negative organisms. Out of these compounds, 3-(4-bromophenyl)-4-(2-(4-nitrophenyl) hydrazinyl)furan-2(5H)-one (4a11) showed the most potent antibacterial activity against S. aureus ATCC 25923 with MIC50 of 0.42 μg/mL. The enzyme assay revealed that the possible antibacterial mechanism of the synthetic compounds might be due to their inhibitory activity against tyrosyl-tRNA synthetase. Molecular dockings of 4a11 into S. aureus tyrosyl-tRNA synthetase active site were also performed. This inhibitor snugly fitting the active site might well explain its excellent inhibitory activity. Meanwhile, this modeling disclosed that a more suitable optimization strategy might be to modify the benzene ring at 3-position of furanone with hydrophilic groups.

4-Alkoxy-3-arylfuran-2(5H)-ones as inhibitors of tyrosyl-tRNA synthetase: Synthesis, molecular docking and antibacterial evaluation

A series of novel 4-alkoxy-3-arylfuran-2(5H)-ones as tyrosyl-tRNA synthetase inhibitors were synthesized. Of these compounds, 3-(4-hydroxyphenyl)- 4-(2-morpholinoethoxy)furan-2(5H)-one (27) was the most potent. The binding model and structure-activity rel

Tyrosyl-tRNA synthetase inhibitors as antibacterial agents: Synthesis, molecular docking and structure-activity relationship analysis of 3-aryl-4-arylaminofuran-2(5H)-ones

Thirty-five 3-aryl-4-arylaminofuran-2(5H)-one derivatives were designed, prepared and tested for their inhibitory activity against tyrosyl-tRNA synthetase. Out of these compounds, 3-(3-bromophenyl)-4-(3,5- dichlorophenylamino)furan-2(5H)-one (35) was the most active with IC 50 of 0.09 ± 0.02 μM. The structure-activity relationship revealed that introduction of chlorine atoms at both meta positions of aniline moiety significantly increased the enzyme inhibitory activity. The results of antibacterial assay revealed that the tested compounds showed good activity against Gram-positive bacteria, with 35 being the most potent with MIC 50 of 0.06 μg/mL against Staphylococcus aureus ATCC 25923. Molecular docking of 35 into S. aureus tyrosyl-tRNA synthetase active site was also performed. The inhibitor snugly fitting the active site may well explain its excellent inhibitory activity.